Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Houston, TX
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
mi
from
Brest,
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
mi
from
Brest,
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Baltimore, MD
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Cleveland, OH
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Charleston, SC
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Corona, CA
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Corona, CA
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Fountain Valley, CA
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Glendale, CA
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Detroit, MI
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Lake Success, NY
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Lake Success, NY
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Durham, NC
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Sylvania, OH
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Sylvania, OH
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
West Reading, PA
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
West Reading, PA
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Falls Church, VA
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Falls Church, VA
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
mi
from
Prairiewood,
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
mi
from
Prairiewood,
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
mi
from
Washington, D.C.,
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas
Randomized Controlled Trial of Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient Controlled Analgesia (3:1) in Patients Undergoing Liver and/or Pancreatic Resection
Status: Enrolling
Updated:  9/26/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas
Randomized Controlled Trial of Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient Controlled Analgesia (3:1) in Patients Undergoing Liver and/or Pancreatic Resection
Status: Enrolling
Updated: 9/26/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Breast
Status: Enrolling
Updated:  9/26/2017
Burzynski Clinic
mi
from
Houston, TX
Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Breast
Status: Enrolling
Updated: 9/26/2017
Burzynski Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Adenocarcinoma of the Colon
Status: Enrolling
Updated:  9/26/2017
Burzynski Clinic
mi
from
Houston, TX
Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Adenocarcinoma of the Colon
Status: Enrolling
Updated: 9/26/2017
Burzynski Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Squamos Cell Carcinoma of the Lung
Status: Enrolling
Updated:  9/26/2017
Burzynski Clinic
mi
from
Houston, TX
Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Squamos Cell Carcinoma of the Lung
Status: Enrolling
Updated: 9/26/2017
Burzynski Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
Phase II Study of Antineoplastons A10 and AS2-1 Capsules In Patients With Non Small Cell Lung Cancer
Status: Enrolling
Updated:  9/26/2017
Burzynski Clinic
mi
from
Houston, TX
Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
Phase II Study of Antineoplastons A10 and AS2-1 Capsules In Patients With Non Small Cell Lung Cancer
Status: Enrolling
Updated: 9/26/2017
Burzynski Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Curcumin in Treating Patients With Familial Adenomatous Polyposis
Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
Status: Enrolling
Updated:  9/27/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Curcumin in Treating Patients With Familial Adenomatous Polyposis
Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
Status: Enrolling
Updated: 9/27/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Curcumin in Treating Patients With Familial Adenomatous Polyposis
Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
Status: Enrolling
Updated:  9/27/2017
Univ of Puerto Rico
mi
from
San Juan,
Curcumin in Treating Patients With Familial Adenomatous Polyposis
Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
Status: Enrolling
Updated: 9/27/2017
Univ of Puerto Rico
mi
from
San Juan,
Click here to add this to my saved trials
RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase II Study of RO4929097 to Eradicate Residual Disease in Patients With Multiple Myeloma Post Single Autologous Stem Cell Transplant
Status: Enrolling
Updated:  9/27/2017
Moffitt Cancer Center
mi
from
Tampa, FL
RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase II Study of RO4929097 to Eradicate Residual Disease in Patients With Multiple Myeloma Post Single Autologous Stem Cell Transplant
Status: Enrolling
Updated: 9/27/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer
Randomized Phase II Trial of Polyphenon E vs.Placebo in Patients at High Risk of Recurrent Colonic Neoplasia
Status: Enrolling
Updated:  9/27/2017
Univ of Illinois
mi
from
Chicago, IL
Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer
Randomized Phase II Trial of Polyphenon E vs.Placebo in Patients at High Risk of Recurrent Colonic Neoplasia
Status: Enrolling
Updated: 9/27/2017
Univ of Illinois
mi
from
Chicago, IL
Click here to add this to my saved trials
Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer
Randomized Phase II Trial of Polyphenon E vs.Placebo in Patients at High Risk of Recurrent Colonic Neoplasia
Status: Enrolling
Updated:  9/27/2017
Hines Veterans Administration Hospital
mi
from
Hines, IL
Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer
Randomized Phase II Trial of Polyphenon E vs.Placebo in Patients at High Risk of Recurrent Colonic Neoplasia
Status: Enrolling
Updated: 9/27/2017
Hines Veterans Administration Hospital
mi
from
Hines, IL
Click here to add this to my saved trials
Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer
Randomized Phase II Trial of Polyphenon E vs.Placebo in Patients at High Risk of Recurrent Colonic Neoplasia
Status: Enrolling
Updated:  9/27/2017
The Mayo Clinic
mi
from
Rochester, MN
Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer
Randomized Phase II Trial of Polyphenon E vs.Placebo in Patients at High Risk of Recurrent Colonic Neoplasia
Status: Enrolling
Updated: 9/27/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Phase I/II Randomized Study of Combination Immunotherapy With or Without Polysaccharide Krestin (PSK®) Concurrently With a HER2 ICD Peptide-Based Vaccine in Patients With Stage IV Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Status: Enrolling
Updated:  9/27/2017
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Phase I/II Randomized Study of Combination Immunotherapy With or Without Polysaccharide Krestin (PSK®) Concurrently With a HER2 ICD Peptide-Based Vaccine in Patients With Stage IV Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Status: Enrolling
Updated: 9/27/2017
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer
Feasibility and Preliminary Outcomes of Survivorship Care Planning in Ovarian Cancer
Status: Enrolling
Updated:  9/27/2017
City of Hope Medical Center
mi
from
Duarte, CA
Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer
Feasibility and Preliminary Outcomes of Survivorship Care Planning in Ovarian Cancer
Status: Enrolling
Updated: 9/27/2017
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Information With or Without Numbers For Optimizing Reasoning About Medical Decisions
Describing the Comparative Effectiveness of Colorectal Cancer Screening Tests: The Impact of Quantitative Information
Status: Enrolling
Updated:  9/27/2017
Indiana University
mi
from
Indianapolis, IN
Information With or Without Numbers For Optimizing Reasoning About Medical Decisions
Describing the Comparative Effectiveness of Colorectal Cancer Screening Tests: The Impact of Quantitative Information
Status: Enrolling
Updated: 9/27/2017
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer
An Open-Label Study Using the Medpulser® Electroporation System to Treat Head and Neck Cancer
Status: Enrolling
Updated:  9/27/2017
Inovio Biomedical Corporation
mi
from
San Diego, CA
Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer
An Open-Label Study Using the Medpulser® Electroporation System to Treat Head and Neck Cancer
Status: Enrolling
Updated: 9/27/2017
Inovio Biomedical Corporation
mi
from
San Diego, CA
Click here to add this to my saved trials
Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer
An Open-Label Study Using the MedPulser Electroporation System to Treat Cutaneous and Subcutaneous Foci of Cancer
Status: Enrolling
Updated:  9/27/2017
Inovio Biomedical Corporation
mi
from
San Diego, CA
Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer
An Open-Label Study Using the MedPulser Electroporation System to Treat Cutaneous and Subcutaneous Foci of Cancer
Status: Enrolling
Updated: 9/27/2017
Inovio Biomedical Corporation
mi
from
San Diego, CA
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Adenocarcinoma of the Lung
Status: Enrolling
Updated:  9/27/2017
Burzynski Clinic
mi
from
Houston, TX
Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Adenocarcinoma of the Lung
Status: Enrolling
Updated: 9/27/2017
Burzynski Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated:  9/27/2017
Burzynski Clinic
mi
from
Houston, TX
Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated: 9/27/2017
Burzynski Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Small Intestine
Status: Enrolling
Updated:  9/27/2017
Burzynski Clinic
mi
from
Houston, TX
Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Small Intestine
Status: Enrolling
Updated: 9/27/2017
Burzynski Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma
A Randomized Trial Comparing Preservation of Function Status After Either Medpulser Electroporation With Intratumoral Bleomycin Therapy or Surgery in Patients With Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Anterior Oral Cavity, Soft Palate, or Tonsil That Have Failed Primary Curative Therapy
Status: Enrolling
Updated:  9/27/2017
Inovio Biomedical Corporation
mi
from
San Diego, CA
Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma
A Randomized Trial Comparing Preservation of Function Status After Either Medpulser Electroporation With Intratumoral Bleomycin Therapy or Surgery in Patients With Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Anterior Oral Cavity, Soft Palate, or Tonsil That Have Failed Primary Curative Therapy
Status: Enrolling
Updated: 9/27/2017
Inovio Biomedical Corporation
mi
from
San Diego, CA
Click here to add this to my saved trials
A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer
A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer
Status: Enrolling
Updated:  9/28/2017
University of Michigan Health Systems
mi
from
Ann Arbor, MI
A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer
A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer
Status: Enrolling
Updated: 9/28/2017
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
A Multicenter Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab Followed By Pemetrexed and Bevacizumab Maintenance Therapy in Patients With a Light or Never Smoking History
Status: Enrolling
Updated:  9/28/2017
CCHC New Bern Cancer Care
mi
from
New Bern, NC
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
A Multicenter Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab Followed By Pemetrexed and Bevacizumab Maintenance Therapy in Patients With a Light or Never Smoking History
Status: Enrolling
Updated: 9/28/2017
CCHC New Bern Cancer Care
mi
from
New Bern, NC
Click here to add this to my saved trials
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
A Multicenter Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab Followed By Pemetrexed and Bevacizumab Maintenance Therapy in Patients With a Light or Never Smoking History
Status: Enrolling
Updated:  9/28/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
A Multicenter Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab Followed By Pemetrexed and Bevacizumab Maintenance Therapy in Patients With a Light or Never Smoking History
Status: Enrolling
Updated: 9/28/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
A Multicenter Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab Followed By Pemetrexed and Bevacizumab Maintenance Therapy in Patients With a Light or Never Smoking History
Status: Enrolling
Updated:  9/28/2017
Mission Hospital, Inc
mi
from
Asheville, NC
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
A Multicenter Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab Followed By Pemetrexed and Bevacizumab Maintenance Therapy in Patients With a Light or Never Smoking History
Status: Enrolling
Updated: 9/28/2017
Mission Hospital, Inc
mi
from
Asheville, NC
Click here to add this to my saved trials
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
A Multicenter Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab Followed By Pemetrexed and Bevacizumab Maintenance Therapy in Patients With a Light or Never Smoking History
Status: Enrolling
Updated:  9/28/2017
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
A Multicenter Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab Followed By Pemetrexed and Bevacizumab Maintenance Therapy in Patients With a Light or Never Smoking History
Status: Enrolling
Updated: 9/28/2017
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Lymph Node Mapping in Patients With Endometrial Cancer
Detection of Sentinel Lymph Nodes in Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes With Fluorescence Imaging
Status: Enrolling
Updated:  9/28/2017
Smilow Cancer Hospital of Yale New Haven
mi
from
New Haven, CT
Lymph Node Mapping in Patients With Endometrial Cancer
Detection of Sentinel Lymph Nodes in Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes With Fluorescence Imaging
Status: Enrolling
Updated: 9/28/2017
Smilow Cancer Hospital of Yale New Haven
mi
from
New Haven, CT
Click here to add this to my saved trials
Lymph Node Mapping in Patients With Endometrial Cancer
Detection of Sentinel Lymph Nodes in Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes With Fluorescence Imaging
Status: Enrolling
Updated:  9/28/2017
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Lymph Node Mapping in Patients With Endometrial Cancer
Detection of Sentinel Lymph Nodes in Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes With Fluorescence Imaging
Status: Enrolling
Updated: 9/28/2017
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated:  9/28/2017
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated: 9/28/2017
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated:  9/28/2017
Oncology Hematology Care
mi
from
Cincinnati, OH
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated: 9/28/2017
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated:  9/28/2017
University of Oklahoma
mi
from
Oklahoma City, OK
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated: 9/28/2017
University of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated:  9/28/2017
Medical University of South Carolina
mi
from
Charleston, SC
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated: 9/28/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated:  9/28/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated: 9/28/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated:  9/28/2017
University of WA Seattle Cancer Care Alliance
mi
from
Seattle, WA
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated: 9/28/2017
University of WA Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials